Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.

ABSTRACT: BACKGROUND:"Avoiding immune destruction" has recently been established as one of the hallmarks of cancer. The programmed cell death (PD)-1/programmed cell death-ligand (PD-L) 1 pathway is an important immunosuppression mechanism that allows cancer cells to escape host immunity. The present study investigated how the expressions of these immune checkpoint proteins affected responses to neo-adjuvant chemotherapy (NAC) in breast cancer. METHODS:A total of 177 patients with resectable early-stage breast cancer were treated with NAC. Estrogen receptor, progesteron receptor, human epidermal growth factor receptor 2, Ki67, PD-L1, PDL-2 and PD-1 status were assessed by immunohistochemistry. RESULTS:There were 37 (20.9%) patients with high PD-1 expression, 42 (23.7%) patients had high PD-L1 express

SUBMITTER: Asano Y 

PROVIDER: S-EPMC5883348 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature